RG3 (Rhodiola)

Ginsenoside Rg3 is a protopanaxadiol-type triterpene saponin isolated primarily from Panax ginseng. Although sometimes grouped with Rhodiola rosea under the adaptogen commercial category, and certain formulations combine the two, Rg3 is a ginseng-derived compound with no Rhodiola botanical origin.

At the molecular level, Rg3 modulates several receptor and ion-channel systems in the central nervous system. It acts as a competitive antagonist at the glycine co-agonist binding site of the NMDA receptor, shifting the glycine concentration-response curve rightward without reducing maximal response. This mechanism reduces excitotoxic calcium influx without fully blocking physiological glutamate signaling. Rg3 also inhibits voltage-gated L-, N-, and P-type calcium channels by interacting with transmembrane domain residues, and exerts use-dependent sodium channel blockade at batrachotoxin-sensitive sites, collectively attenuating neuronal hyperexcitability.

• GABAergic: Rg3 activates GABA-A receptors via a γ2-subunit-dependent mechanism and potentiates GABA-evoked inhibitory currents. • Anti-inflammatory: suppresses NF-κB, COX-2, IL-1β, IL-6, and TNF-α in microglia and hippocampal tissue, reducing neuroinflammatory tone. • Mitochondrial: inhibits mitochondrial permeability transition pore opening and scavenges reactive oxygen species. • Neurotrophic: enhances BDNF expression and CREB phosphorylation, supporting synaptic plasticity and neuronal survival.

Preclinical data for Rg3 in cognitive function are substantial; human cognitive trial data are largely absent.

In animal models, an Rg3-enriched ginseng extract administered orally to male C57BL/6 mice (n=10/group) for 14 days prevented scopolamine-induced spatial memory acquisition deficits in the Morris water maze and suppressed hippocampal acetylcholinesterase activity and NF-κB phosphorylation (BMC Complement Altern Med, PMID 26887326, 2016). Memory retention deficits were not significantly reversed. Zhang et al. (J Agric Food Chem, PMID 31422666, 2019) demonstrated in an Alzheimer's disease rat model that Rg3 reduced cognitive impairment by normalizing mitochondrial energy metabolism, electron transport chain function, amino acid and purine metabolism, and antiapoptotic pathways.

The strongest human evidence for Rg3 comes from oncological RCTs, not cognitive ones. A meta-analysis of 22 RCTs (n=2,202; Frontiers in Pharmacology, 2021) found Rg3 combined with first-line NSCLC chemotherapy improved objective response rate by 44% and reduced myelosuppression versus chemotherapy alone. A separate meta-analysis of 18 RCTs (n=2,222) confirmed hematological recovery improvements. Neither trial population assessed cognitive endpoints.

For neurological and cognitive use, evidence derives from animal models, mechanistic laboratory work, and anecdotal functional medicine case series involving compounded Rg3 intranasal sprays. A 2024 Frontiers in Pharmacology review summarized animal and in-vitro evidence for Rg3 in depression, anxiety, PTSD, and ADHD models, noting one open-label pilot combining Korean red ginseng with omega-3 fatty acids showed ADHD symptom improvement, but that study was non-blinded and cannot isolate Rg3's contribution. No peer-reviewed RCTs evaluating Rg3 specifically for cognitive enhancement in healthy or cognitively impaired humans have been published.

Typical dosage: 3-6 mg (daily).

In Chinese cancer adjuvant RCTs, oral Rg3 (Shenyi Capsule) was administered at 20 mg twice daily (40 mg/day total) per treatment cycle, representing the most consistently reported human dosing in the published literature.

Toxicology data: a 26-week repeated-dose oral study in Sprague-Dawley rats established a no-observed-adverse-effect level (NOAEL) of 180 mg/kg with no mortality, organ pathology, or hematological abnormalities at any tested dose. Beagle dog NOAEL was reported at 20 mg/kg. Human intramuscular safety studies tolerated single doses up to 60 mg/kg and repeated dosing at 30 mg/kg every two days for 15 days. Oral clinical trials in humans have found no toxicity at doses up to 50 mg/day.

In compounded intranasal formulations such as Synapsin (pairing Rg3 with nicotinamide riboside and methylcobalamin), functional medicine practitioners typically begin with one spray per nostril once daily, titrated to response up to a maximum of two sprays per nostril three times daily. Each spray delivers an estimated 0.5–1 mg Rg3, though concentrations vary by compounding pharmacy and no standardized dosing protocol has been validated in an RCT.

This content is for educational purposes only and does not constitute medical advice. Ginsenoside Rg3 is not FDA-approved for any cognitive indication; in the United States it is available only through compounding pharmacies or as a research chemical. A licensed healthcare provider should be consulted before use.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most documented combination in functional medicine practice pairs Rg3 with nicotinamide riboside (NR, a NAD+ precursor) and methylcobalamin (vitamin B12) in the compounded intranasal Synapsin formulation. The rationale is complementary neuroprotection: Rg3 targets microglial neuroinflammation while NR supports mitochondrial NAD+ repletion; no peer-reviewed RCT has evaluated this combination for cognitive outcomes.

A traditional Chinese medicine formula designated YY162 combines Rg3 with Ginkgo biloba extract; animal studies suggest additive effects on oxidative metabolism and the BDNF/TrkB pathway in ADHD models, but human data are absent.

Nootropic community practitioners anecdotally stack Rg3 with Rhodiola rosea (for complementary HPA-axis modulation and stress resilience), lion's mane mushroom (for NGF pathway support), and bacopa monnieri (for cholinergic augmentation). These combinations are entirely anecdotal and lack any controlled human evidence.

RG3 (Rhodiola) is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Well-tolerated

A 26-week oral toxicology study in mice and rats (up to 180 mg/kg) found no mortality, no clinical toxicity signs, no hematological or biochemical abnormalities, and no histopathological lesions at any tested dose. Human cancer adjuvant trials at approximately 40 mg/day reported no serious adverse events in pooled populations exceeding 2,000 patients across meta-analyses.

Adverse effects documented in ginseng product literature and observational reports include: gastrointestinal discomfort (nausea, diarrhea), insomnia, headache, dizziness, blood pressure fluctuations (both hypertensive and hypotensive episodes), vaginal bleeding, and mastalgia. An in-vitro study found that Rg3 can induce phosphatidylserine exposure on erythrocytes, raising a theoretical pro-thrombotic concern; clinical significance has not been established in vivo.

Drug interactions of concern include: anticoagulants and antiplatelet agents (potential increased bleeding risk), antihypertensive medications (additive hypotension), hypoglycemic drugs (additive glucose-lowering with hypoglycemia risk), and monoaminergic agents including SSRIs and MAOIs. Rg3 shares ginseng's putative estrogenic activity; individuals with hormone-sensitive conditions such as estrogen-receptor-positive breast cancer or endometriosis should exercise caution.

Intranasal formulations are generally well-tolerated; transient nasal stinging or burning is the primary reported local effect. Long-term safety specifically for cognitive enhancement use cannot be established given the complete absence of dedicated human trials for this indication.